Please ensure Javascript is enabled for purposes of website accessibility

Why Exelixis, Inc. Is Trading Higher Today

By Brian Orelli, PhD - Dec 23, 2015 at 2:43PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The biotech submitted a marketing application for its kidney cancer drug.

What: Exelixis (EXEL 1.30%) is up 11% at 3:00 p.m. EST after announcing that it had completed its FDA marketing application to sell cabozantinib as a treatment for kidney cancer patients that had progressed on a prior treatment.

So what: Submitting the marketing application starts the clock for the FDA to make an approval decision. Exelixis requested a priority review -- an eight-month review -- which the biotech should get since the FDA recently granted Breakthrough Therapy designation to cabozantinib after the phase 3 Meteor clinical trial showed that the drug worked better than Novartis' Afinitor.

The approval could come much faster than eight months. Last month, Bristol-Myers Squibb (BMY 1.49%) received approval for its kidney cancer drug Opdivo just seven days after Bristol-Myers Squibb announced that the FDA had accepted its application.

Seven days!

FDA acceptances usually happen two-months after submission, so Exelixis could conceivably hear from the agency in early March. More realistically, the approval may take a little longer because Bristol-Myers Squibb submitted a Supplementary New Drug Application (sNDA) for Opdivo, whereas Exelixis' application is a full NDA, requiring the FDA to review more documents associated with manufacturing and such.

Now what: While filing its marketing application and preparing to battle Bristol-Myers Squibb for kidney cancer patients is good news, it's hard to see how it's worthy of an 11% price increase since management had previously said that it would submit the application by the end of the year. Eight days before the self-imposed deadline hardly seems worthy of a valuation bump, although Exelixis is still trading lower than the highs set in August after the Meteor clinical trial data were released, so maybe investors are just relieved that the company met its goal.

Brian Orelli has no position in any stocks mentioned. The Motley Fool recommends Exelixis. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exelixis, Inc. Stock Quote
Exelixis, Inc.
EXEL
$19.48 (1.30%) $0.25
Bristol Myers Squibb Company Stock Quote
Bristol Myers Squibb Company
BMY
$75.57 (1.49%) $1.11

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
400%
 
S&P 500 Returns
128%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 08/14/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.